Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054
=============================================================================================================================================

* Alexander Eggermont
* Michal Kicinski
* Stefan Suciu